A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis.
about
Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb studyNew Oral Therapies for Psoriasis: A Comprehensive ReviewUpdates on Psoriasis and Cutaneous Oncology: Proceedings from the 2015 MauiDerm MeetingUpdates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting based on presentations by.JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.Novel Oral Therapies for Psoriasis and Psoriatic Arthritis.JAK inhibition in inflammatory bowel disease.Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.Advances of small molecule targeting of kinases.The Effect of Verapamil, a P-Glycoprotein Inhibitor, on the Pharmacokinetics of Peficitinib, an Orally Administered, Once-Daily JAK Inhibitor.Drug Interactions Between Peficitinib, an Orally Administered, Once-Daily Janus Kinase Inhibitor, and Rosuvastatin in Healthy Subjects.JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling.Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study.JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.Advances in treating psoriasis in the elderly with small molecule inhibitors.Pharmacokinetics, Pharmacodynamics, and Safety of ASP015K (Peficitinib), a New Janus Kinase Inhibitor, in Healthy Subjects.A new option on the horizon for the treatment of psoriasis: it is needed, but not at any price.
P2860
Q24658506-019280D0-1D0D-4FFE-9ECD-610D7ED2F177Q28071475-48F60472-2094-432B-AF87-DD8C9F06379BQ35822379-03AFDFFA-47E3-4A93-964F-E4DFED667F57Q37362082-09CAB936-E463-40C8-9BEF-E61F89F0DD6BQ38751230-B4E43796-4CE4-4F56-AFEB-7D126FB54B4DQ38753877-48AD4D4E-D507-4F1C-AD50-E4F1BC07D56EQ38761142-0D260895-B9C4-4AA2-B29D-6E12C106FB75Q39055724-86215F8F-07CD-4F6A-A4C8-01931A26BDABQ39450797-F6D0F5B7-78C1-4A47-A51D-90F401B7A349Q45930783-5CFFE89C-8E2F-47C9-8438-59861D00B18BQ46088850-08AD523E-EDCE-411F-AEA0-C30A224B9558Q47439880-8FF247D0-5CD0-419F-AEF9-682DB6C83006Q47668330-3AF89D59-B8CB-4DCF-BD31-5075ECAE0A22Q47851802-C18E5E93-D519-440E-9669-44C3EF75FE89Q48109284-62C9F189-108E-48D9-97C2-0BDE195DF2FDQ48556502-36351F46-057F-4213-BB14-2A9667A95BDEQ49679446-7343EE01-2AD6-4E58-A23D-0579B86FC2C5Q50900106-D0AF5378-0834-4609-A1EF-25F3779A5D2CQ54405644-287D3588-5636-4119-8972-E79630965620
P2860
A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A phase 2a randomized, double- ...... moderate-to-severe psoriasis.
@en
A phase 2a randomized, double- ...... moderate-to-severe psoriasis.
@nl
type
label
A phase 2a randomized, double- ...... moderate-to-severe psoriasis.
@en
A phase 2a randomized, double- ...... moderate-to-severe psoriasis.
@nl
prefLabel
A phase 2a randomized, double- ...... moderate-to-severe psoriasis.
@en
A phase 2a randomized, double- ...... moderate-to-severe psoriasis.
@nl
P2093
P356
P1476
A phase 2a randomized, double- ...... h moderate-to-severe psoriasis
@en
P2093
B Akinlade
J G Krueger
P304
P356
10.1111/BJD.13745
P407
P50
P577
2015-06-19T00:00:00Z